TTR and heart failure: Treatment for ATTR-mt has significantly advanced with the approval of tafamidis, a drug that stabilizes the TTR tetramer and prevents its misfolding and subsequent amyloid fibril formation, thereby improving survival and reducing the progression of heart failure, particularly in individuals with the Val30Met mutation.